American Heart Association Journals Circulation Representing the best in the field of cardiovascular medicine and science as well as basic science Editor-in-Chief: Joseph A Hill, MD, PhD View latest issue
2026 AHA ACC ACCP ACEP CHEST SCAI SHM SIR SVM SVN Guideline for the . . . Category E1 is compatible with SCAI SHOCK stage C 3 Category E2 is defined by refractory cardiogenic shock (SCAI D-E) or cardiac arrest without restoration of spontaneous circulation after 30 minutes of resuscitation Respiratory failure in category E-R is defined by the need for noninvasive or invasive positive pressure ventilation
Reactivation of Oxidized Soluble Guanylate Cyclase as a Novel Treatment . . . Pharmacological treatments for fibrocalcific aortic valve stenosis (FCAVS) have been elusive for >50 years Here, we tested the hypothesis that reactivation of oxidized sGC (soluble guanylate cyclase), the primary receptor for nitric oxide, with ataciguat is a safe and efficacious strategy to slow progression of FCAVS
| AHA ASA Journals Circulation publishes original research manuscripts, review articles, and other content related to cardiovascular health and disease, including observational studies, clinical trials, epidemiology, health services and outcomes studies, and advances in basic and translational research
2025 AHA ACC AANP AAPA ABC ACCP ACPM AGS AMA ASPC NMA PCNA SGIM . . . High blood pressure is the most prevalent and modifiable risk factor for the development of cardiovascular diseases, including coronary artery disease, heart failure, atrial fibrillation, stroke, dementia, chronic kidney disease, and all-cause mortality The overarching blood pressure treatment goal is <130 80 mm Hg for all adults, with additional considerations for those who require
2025 ACC AHA HRS ISACHD SCAI Guideline for the Management of Adults . . . The biventricular circulation and systemic left ventricle share the greatest anatomic and physiological similarities with heart failure patients in clinical trials; extrapolation from the heart failure literature is most appropriate in this population
Risk-Based Primary Prevention of Heart Failure: A Scientific Statement . . . The growing morbidity, mortality, and health care costs related to heart failure (HF) underscore the urgent need to prioritize its primary prevention Whereas a risk-based approach for HF prevention remains in its infancy, several key opportunities exist to actualize this paradigm in clinical practice First, the 2022 American Heart Association American College of Cardiology Heart Failure